TriSalus Life Sciences, Inc.

TLSI

US89680M1018

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 03:30:00 15/05/2024 am IST			5-day change	1st Jan Change
9.39 ^USD	-7.49%		-4.48%	+11.12%

15/05	TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/05	Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	MT

TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) added to S&P TMI Index

December 18, 2023 at 10:30 am IST

Latest news about TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	15/05	MT
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024	15/05	CI
TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors	07/05	CI
TriSalus Life Sciences Obtains $50 Million Debt Facility	01/05	MT
TriSalus Life Sciences, Inc. announced that it expects to receive $50 million in funding from OrbiMed Advisors LLC	30/04	CI
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04	CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Reports Q4 Revenue $5.7M	01/04	MT
TriSalus Life Sciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023; Provides Revenue Guidance for the Full Year 2024	12/03	CI
Haystack Oncology Enters A Research Collaboration with TriSalus Life Sciences to Evaluate Therapeutic Response and Provide Molecular Insights in Connection with the Clinical Development of TriSalus' SD-101	22/01	CI
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) added to S&P TMI Index	18/12	CI
TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of New Technology Healthcare Common Procedure Coding System Code	14/12	CI
Transcript : TriSalus Life Sciences, Inc., Q3 2023 Earnings Call, Nov 14, 2023	14/11
TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q3 Revenue $5.2M	14/11	MT
TriSalus Life Sciences, Inc. Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma At the Society for Immunotherapy of Cancer Annual Meeting	03/11	CI
TriSalus Life Sciences, Inc. announced that it expects to receive $100.003 million in funding	02/23/02	CI
TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics	06/23/06	CI
Top Premarket Decliners	16/23/16	MT
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) added to NASDAQ Composite Index	11/23/11	CI
TriSalus Life Sciences, Inc. announced that it has received funding from Frankenius Equity AB	10/23/10	CI
TriSalus Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	21/23/21	CI
TriSalus Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	06/23/06	CI

Chart TriSalus Life Sciences, Inc.

Duration

Period

More charts

TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Companyâs platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.

Sector

Biotechnology & Medical Research

Calendar

12/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.85 USD

Average target price

16 USD

Spread / Average Target

+62.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRISALUS LIFE SCIENCES, INC.	+11.12%	264M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.71%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs